Oxidoreductases (1. ) (e.g., Catalase, Dehydrogenases, Reductases, Etc.) Patents (Class 424/94.4)
-
Publication number: 20110280855Abstract: The field of invention relates to Vitamin C compositions, and in particular to Vitamin C compositions containing ascorbate-glucose transport enhancers. In at least one aspect, a composition is provided herein that includes ascorbate in an amount from about 0.1% by weight of actives to about 99.9% by weight of actives, and at least one ascorbate-glucose transport enhancer in an amount from about 0.01% by weight of actives to about 99.0% by weight of actives. In other aspects, methods of improving the transport of ascorbate into cells and tissues, and improving the ascorbate or antioxidant status of a person, are provided that include providing a composition comprising ascorbate and at least one ascorbate-glucose transport enhancer.Type: ApplicationFiled: June 3, 2011Publication date: November 17, 2011Inventor: Neil Levin
-
Publication number: 20110274738Abstract: Provided herein are methods for functionalizing a polymer for forming a coating and coatings and devices formed thereof or for functionalizing a coating or device surface including an polymer.Type: ApplicationFiled: July 19, 2011Publication date: November 10, 2011Inventors: Stephen Dirk Pacetti, Syed Faiyaz Ahmed Hossainy
-
Publication number: 20110274680Abstract: Synergistic chemical compositions of bioactive compounds in a dietary supplement for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases; chemical compositions of a sugar free super sweetener for people with Type-2 Diabetes disease and a targeted nano delivery of bioactive compounds and/or bioactive molecules are described. Furthermore, microelectro-mechanical system (Mems) based passive and active (based on feedback diagnostics data) delivery systems and methods of bioactive compounds and/or bioactive molecules are also described.Type: ApplicationFiled: July 15, 2011Publication date: November 10, 2011Inventors: Mohammad A. Mazed, Sayeeda Mazed
-
Publication number: 20110268713Abstract: The present invention provides uricases and methods of their production and use in reducing the amount of uric acid in a subject. The present invention further provides methods employing a uricase of this invention in the treatment and/or prevention of hyperuricemia, gout, tumor lysis syndrome and/or hypertension in a subject.Type: ApplicationFiled: April 8, 2011Publication date: November 3, 2011Inventor: Eric A. Gaucher
-
Publication number: 20110268719Abstract: Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation.Type: ApplicationFiled: July 13, 2011Publication date: November 3, 2011Applicant: AMERICAN RIVER NUTRITION, INC.Inventor: Barrie TAN
-
Publication number: 20110262421Abstract: It is intended to provide a pharmaceutical composition, a food or drink, or a feed which has an effect on the prevention and/or treatment of an intestinal disease such as ulcerative colitis, Crohn's disease or irritable bowel syndrome. A preferred embodiment is the pharmaceutical composition, food or drink, or feed which contains lactoperoxidase as an active ingredient and has an effect on the prevention and/or treatment of an intestinal disease, wherein the intestinal disease is at least one disease selected from ulcerative colitis, Crohn's disease and irritable bowel syndrome.Type: ApplicationFiled: July 6, 2011Publication date: October 27, 2011Applicant: MORINAGA MILK INDUSTRY CO., LTD.Inventor: Kouichirou Shin
-
Publication number: 20110265198Abstract: Disclosed herein are methods and compositions for genome editing of a Rosa locus, using fusion proteins comprising a DNA binding domain and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.Type: ApplicationFiled: April 25, 2011Publication date: October 27, 2011Inventors: Philip D. Gregory, Michael C. Holmes
-
Publication number: 20110262505Abstract: A cosmetic composition is disclosed for applying to skin. The composition includes a liquid and dispersed in the liquid: any amount or form of fucoidan, any amount or form of beta glucan; and any amount of a marine extract. When the cosmetic composition is applied to the skin, the appearance of the skin is improved.Type: ApplicationFiled: April 22, 2011Publication date: October 27, 2011Inventor: Gina Athwal
-
Publication number: 20110262420Abstract: An inhalant containing a lecithinized superoxide dismutase (hereinafter referred to as PC-SOD) which effectively exerts the effect of superoxide dismutase (SOD) as an active ingredient, particularly for treatment of idiopathic (acute) or chronic interstitial pneumonia, is provided. The inhalant includes a PC-SOD represented by the following general formula (I): SOD?(Q?B)m??(I) (wherein SOD? is a residue of the superoxide dismutase; Q is a chemical crosslinking; B is a residue without a hydrogen atom of a hydroxyl group of lysolecithin having the hydroxyl group at the 2-position of glycerol; and m is the average number of bonds of lysolecithin to one molecule of superoxide dismutase and is an integer of 1 or more).Type: ApplicationFiled: November 9, 2009Publication date: October 27, 2011Applicant: LTT Bio-Pharma Co., Ltd.Inventor: Toru Mizushima
-
Patent number: 8034384Abstract: A material includes a surface and a reactive agent that is located at the surface of the material, covalently attached to a backbone of the material, and/or located within the material. The reactive agent has nitrite reductase activity, nitrate reductase activity, and/or nitrosothiol reductase activity. The reactive agent also converts at least one of nitrites, nitrates and nitrosothiols to nitric oxide when in contact with blood. A reproducible nitrosothiol sensor is also disclosed.Type: GrantFiled: November 21, 2007Date of Patent: October 11, 2011Assignee: The Regents of The University of MichiganInventors: Mark E. Meyerhoff, Melissa M. Reynolds, Megan Frost, Sangyeul Hwang, Yiduo Wu
-
Publication number: 20110243911Abstract: The present invention is directed to the use of a compound capable of reducing the uric acid level in a mammal for the prevention and/or the treatment of IL-1? driven lung pathology, particularly to treat lung inflammation such as chronic fibrosis, COPD and interstitial fibrosis and other IL-1? driven lung pathologies including those of autoimmune origin. Preferred compounds capable of reducing the uric acid level are selected from the group consisting of xanthine oxidase inhibitors, such as allopurinol, recombinant enzyme uricase and uricosuric compound capable of enhancing uric acid excretion, such as probenecid. The invention further relates to a method for identifying in vitro whether a patient presents an IL-1? driven lung pathology or is at risk to develop an IL-1? driven lung pathology, or for the screening of a compound for treating an IL-1? driven lung pathology.Type: ApplicationFiled: September 18, 2009Publication date: October 6, 2011Inventors: Bernhard Ryffel, Isabelle Couillin
-
Publication number: 20110244017Abstract: The present invention provides an absorbable coating for an implantable device and the methods of making and using the same.Type: ApplicationFiled: March 31, 2010Publication date: October 6, 2011Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.Inventors: Lothar W. Kleiner, Syed F.A. Hossainy, Mikael Trollsas, Stephen D. Pacetti
-
Patent number: 8029830Abstract: The present invention relates to a new composition comprising substances that promote DNA repair, reduce body fat levels and increase lean body mass and that decrease wrinkle appearance and/or improvement in skin surface. In some aspects, the composition of the present invention include resveratrol, forskohlin and astaxanthin. In another aspect the composition of the present invention further comprises carboxy alkyl ester. The present invention also relates to a method of promoting internal health and external appearance in a subject in need, said method comprising administering to the subject a composition that promotes DNA repair, reduces body fat levels and increases lean body mass and that decreases wrinkle appearance and/or improvement in skin surface.Type: GrantFiled: January 8, 2009Date of Patent: October 4, 2011Assignee: Nuvocare Health Services Inc.Inventor: Ryan Jason Foley
-
Patent number: 8029816Abstract: The present invention is directed to medical devices including coatings. The coatings include a topcoat which includes a copolymer comprising a block of an elastin pentapeptide. The topcoat is over a layer of poly(vinyl alcohol) on a hydrophobic coating or over a porous coating comprising pores or depots that include a bioactive agent.Type: GrantFiled: May 10, 2007Date of Patent: October 4, 2011Assignee: Abbott Cardiovascular Systems Inc.Inventors: Syed Faiyaz Ahmed Hossainy, Yiwen Tang, Lothar W. Kleiner
-
Publication number: 20110236394Abstract: AKR1B1 (EC 1.1.1.21) is an aldose reductase that has mainly been associated with the polyol pathway, and more recently with lipid deperoxidation. We have discovered that the primary activity of this enzyme is rather a PGFS activity, catalyzing the transformation of PGH2 into PGF2?. AKR1B1 as a therapeutic target, and method for modulating its expression and activity are provided. Methods for regulating the expression and activity of PGF2? are also provided.Type: ApplicationFiled: November 14, 2008Publication date: September 29, 2011Applicant: UNIVERSITE LAVALInventors: Michel Fortier, Pierre Chapdelaine, Eva Bresson, Eric Madore
-
Publication number: 20110236365Abstract: Methods and compositions for enhancing cellular function through protection of a tissue components such receptors, proteins, lipids, nucleic acids, carbohydrates, hormones, vitamins, and cofactors, by administering pyrophosphate analogs or related compounds.Type: ApplicationFiled: May 17, 2011Publication date: September 29, 2011Applicant: HealthPartners Research FoundationInventors: William H. Frey, II, John Randall Fawcett
-
Publication number: 20110229449Abstract: The present invention provides an agent for the prophylaxis or treatment of retinopathy or AMD containing PRDX 5 or PRDX 6, as well as an agent for the prophylaxis or treatment of retinopathy or AMD containing a polynucleotide encoding PRDX 5 or PRDX 6. The present invention also provides a method for the prophylaxis or treatment of retinopathy or AMD in a patient suffering from the disease, which includes administering to the patient an effective amount of PRDX 5 or PRDX 6, or administering to the patient an effective amount of a polynucleotide encoding PRDX 5 or PRDX 6.Type: ApplicationFiled: March 4, 2010Publication date: September 22, 2011Applicant: National University Corporation University of FukuiInventors: Eri Kubo, Dhirendra Pratap Singh
-
Publication number: 20110229598Abstract: The present invention relates to treatment of milk and milk products such as waste-milk with an enhanced lactoperoxidase system. The enhanced lactoperoxidase system is activated by the addition of a hydrogen peroxide source and an oxidizable agent, such as a halide to the milk to inactivate the bacterial pathogens. The enhanced lactoperoxidase system may be used alone or in conjunction with pasteurization to reduce or eliminate the bacterial load in milk products.Type: ApplicationFiled: March 11, 2011Publication date: September 22, 2011Applicant: Land O'Lakes Purina Feed LLCInventor: Robert C. Musser
-
Publication number: 20110223230Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: ApplicationFiled: May 19, 2011Publication date: September 15, 2011Applicant: ASCENDIS PHARMA A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Publication number: 20110217279Abstract: The present invention is directed to methods of modulating PKC-? activity and PKC-?/ERK complex activity in cells via biliverdin reductase. Methods and compositions for diagnosing and treating a PKC-? and PKC-?/ERK complex related condition are also disclosed.Type: ApplicationFiled: November 8, 2010Publication date: September 8, 2011Applicant: UNIVERSITY OF ROCHESTERInventor: Mahin D. MAINES
-
Publication number: 20110212072Abstract: Described are a method and a composition for preventing and/or treating a disease related to mitochondrial dysfunction by inhibiting the fatty acid oxidation of one or more cells of an organism. Particularly, the fatty acid oxidation is inhibited by inhibiting the expression and/or activity of the enzyme Camitin-Palmitoyl-Transferase-1 (CPT-1) by means of an arylalkyl- or arlyoxyalkyl-substitued oxirane carboxylic acid or pharmaceutically acceptable salts and derivatives of the arylalkyl-substituted oxirane carboxylic acid.Type: ApplicationFiled: April 19, 2011Publication date: September 1, 2011Applicant: MediGene AGInventors: Thomas Henkel, Christoph Rehfuess
-
Patent number: 8007786Abstract: The invention refers to a specific isoform of MnSOD (Mn-superoxide dismutase) and its uses for protecting and curing subjects exposed to radiations, specifically space radiations.Type: GrantFiled: October 20, 2009Date of Patent: August 30, 2011Assignee: Asi Agenzia Spaziale ItalianaInventor: Aldo Mancini
-
Publication number: 20110206653Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation. In Formula 1, x is 1 or 2: y is O, 1, 2 or 3; and R1 is selected from the group consisting of hydrogen, alkyl having 1 or 2 carbon atoms, hydroxy, alkoxy having 1 or 2 carbon atoms, fluoro, chloro, bromo, and amino.Type: ApplicationFiled: April 30, 2009Publication date: August 25, 2011Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: James Dennen O'Neil, Shalini Sharma, Ramachandran Arudchandran
-
Publication number: 20110200660Abstract: A method of forming a coating on a medical device having a controlled morphology is described. A medical device having a controlled morphology is described.Type: ApplicationFiled: February 28, 2011Publication date: August 18, 2011Applicant: Advanced Cardiovascular Systems, Inc.Inventors: Lothar Walter Kleiner, Jessica Reneé DesNoyer, Stephen Dirk Pacetti, Syed Faiyaz Ahmed Hossainy
-
Publication number: 20110200575Abstract: Formulations are provided for the improvement of sleep patterns. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as 5-hydroxy-L-tryptophan (5-HTP), choline, melatonin, milk protein hydrolysate, L-arginine, and L-carnitine. The compositions can be administered orally in a variety of forms.Type: ApplicationFiled: April 28, 2011Publication date: August 18, 2011Applicant: Naidu LPInventors: A. Satyanarayan Naidu, A.G. Tezus Naidu, A.G. Sreus Naidu
-
Publication number: 20110197294Abstract: The invention provides methods and compositions for treating, ameliorating or preventing diseases or conditions caused by or aggravated by lost and/or impaired mitochondrial Complex I function, including treating, ameliorating or preventing an ischemia and/or reperfusion injury, Parkinson's disease, myopathic diseases, cardiolipin deficiency, neurodegenerative diseases, aging, diabetes, obesity, sepsis and other conditions in which mitochondrial Complex I function is lost and/or impaired.Type: ApplicationFiled: June 4, 2009Publication date: August 11, 2011Inventors: Roberta A. Gottlieb, Cynthia Perry
-
Publication number: 20110195039Abstract: A method of treating hair comprising applying a hair building solid agent for use on or with one or more of hair, skin and hair building solids for altering and/or maintaining the electrostatic charge of the hair and/or skin such that it has a substantially negative polarity. The method further comprises applying hair building solids to hair before and/or during and/or after applying the hair building solid agent. The hair building solid agent is applied as a spray on to the hair and/or skin and/or hair building solid.Type: ApplicationFiled: February 11, 2011Publication date: August 11, 2011Applicant: PANGAEA LABORATORIES LTD.Inventor: Elliot Isaacs
-
Publication number: 20110189166Abstract: Methods of treating hemorheologic abnormalities in mammals are provided, as well as methods of evaluating circulatory flow mechanics by analyzing hemorheologic determinants or hemorheologic abnormalities in the blood.Type: ApplicationFiled: January 29, 2011Publication date: August 4, 2011Inventor: John BOUCHER
-
Publication number: 20110189154Abstract: Applications of a new class of enzymes, sulfiredoxines (Srx), catalyzing the reduction of Cys-SO2#191H (sulfinic cystein acid) and the reduction of peroxyredoxine (Prx) in the Cys-SO2#191H form thereof into a thiol derivative.Type: ApplicationFiled: July 2, 2004Publication date: August 4, 2011Inventors: Michel Toledano, Benoît Biteau
-
Patent number: 7989554Abstract: A new method of preparing a tertiary alkyl ester of a polyalkylene oxide is provided. The new method employs milder conditions that avoid the back reaction to the starting polyalkylene oxide. The tertiary alkyl ester of a polyalkylene oxide is then reacted with a suitable acid to produce a polyalkylene oxide acid.Type: GrantFiled: January 10, 2006Date of Patent: August 2, 2011Assignee: Enzon Pharmaceuticals, Inc.Inventors: Hong Zhao, Anthony J. Martinez
-
Publication number: 20110176994Abstract: The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems for direct delivery of therapeutic agents into the central nervous system.Type: ApplicationFiled: March 18, 2011Publication date: July 21, 2011Applicant: seaCoast NeuroScience, Inc.Inventors: Daniel Pratt, Samuel S. MacAusland, Keith Baker
-
Publication number: 20110177140Abstract: This invention relates to the use of 4-amidino benzylamine derivatives as cosmetic ingredients and to cosmetic compositions, as well as to non-therapeutic methods for the cosmetic treatment of the skin and the scalp. Said derivatives and compositions can be used as urokinase inhibitors to prevent and restore damage of the epidermal barrier. Barrier abnormalities and disruptions respectively are often the starting point of a dry skin state, of itching, of dandruff and of the perception of sensitive skin. These 4-amidino benzylamine derivatives can be used for topical skin and scalp care applications in form of creams, lotions, gels, shampoos and the like.Type: ApplicationFiled: August 31, 2007Publication date: July 21, 2011Inventors: Rainer Voegeli, Hugo Ziegler, Mathias Gempeler
-
Publication number: 20110177054Abstract: The present invention relates to a method for determining the delivery rates and/or efficiency of a siRNA, miRNA or related molecule to target organs or cells, a kit and the use of proteins or lipids involved in the formation of the endolysosomal system for modulating the activity and/or the cell-to-cell transfer of RNA, small RNA, for example miRNA, siRNA and piRNA, mRNA or non-coding RNA. It finds many applications in particular in methods for identifying the target(s) of miRNA or siRNA therapeutics, in methods for determining the efficiency of a treatment with siRNA and/or miRNA therapeutics, in methods for determining the efficiency of a treatment with siRNA and/or miRNA therapeutics, and in methods for genotyping and/or characterizing the condition of a person, a tumor or a fetus.Type: ApplicationFiled: June 5, 2009Publication date: July 21, 2011Inventors: Derrick Gibbings, Olivier Voinnet
-
Publication number: 20110171193Abstract: Provided herein are methods and materials for treating pulmonary hypertension (PH) in a subject. Also provided herein is a method of diagnosing whether a has PH by detecting a PH marker. A PKG pulmonary hypertension marker has been identified and may be useful in predicting PH disease progression and assessing a subject's response to PH therapy.Type: ApplicationFiled: June 12, 2009Publication date: July 14, 2011Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: You-Yang Zhao, Asrar B. Malik
-
Publication number: 20110171264Abstract: An aqueous composition which comprises a protein or other biological molecule and also (i) optionally comprises one or more metal ions at a concentration of 0.01 to 20 mM; (ii) comprises excipients which are weak ligands; and (iii) is substantially free of excipients which are medium-strength ligands or strong ligands.Type: ApplicationFiled: October 28, 2010Publication date: July 14, 2011Inventor: Jan Jezek
-
Publication number: 20110171268Abstract: Compositions containing uricase are disclosed. Methods of treating a disorder associated with elevated uric acid concentrations using uricase are also described. Compositions containing uricase and catalase are also disclosed. Methods of treating a disorder associated with elevated uric acid concentrations using uricase and catalase are also described.Type: ApplicationFiled: March 24, 2009Publication date: July 14, 2011Applicant: Althea Technologies, Inc.Inventors: Bhami Shenoy, Danica Grujic, Reena Patel, Vinney George, Margaret Mcgrath, Nazer Khalaf, Emma Watson
-
Publication number: 20110171192Abstract: A compound represented by following general formula (I): wherein, represents a single bond or a double bond; L represents —NH— or the like; X1 represents N or C, provided that in the case where X1 is N, X2 represents C—R and in the case where X1 is C, X2 represents N—R1 or the like; Y's may be either the same or different and represent CH2 or the like; A represents a non-natural sugar residue represented by following general formula: wherein, m represents 0 to 1; represents a single bond or a double bond; X represents O or the like; R3 to R8 may be either the same or different and represent hydroxy group or the like; and B represents a group represented by following general formula: wherein, n and k represent 0 to 5; represents a single bond or a double bond; Z1 to Z16 may be either the same or different and represent CH or the like; R10 and R11 may be either the same or different and represent a lower alkoxy group having 1 to 5 carbon atoms or the like; and R15 represents a hydrogen atom or thType: ApplicationFiled: August 27, 2009Publication date: July 14, 2011Inventors: Hiroshi Tomiyama, Kazuo Tokuzaki, Yoshinori Iwai
-
Publication number: 20110171194Abstract: This invention provides methods, compositions and articles of manufacture for inhibiting binding between A? protein and ABAD in cells. Uses of this invention include, for example, treating Alzheimer's disease; reducing free radical generation, DNA fragmentation, and cytochrome C release in cells; and preserving cell viability by preventing LDH release from a cell.Type: ApplicationFiled: January 13, 2011Publication date: July 14, 2011Inventors: Shi Du Yan, David M. Stern, Joyce W. Lustbader, Hao Wu
-
Patent number: 7976876Abstract: The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) a mixture of a coenzyme having reducing ability and a quinone, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard.Type: GrantFiled: September 29, 2008Date of Patent: July 12, 2011Assignee: Well-Being Biochemical Corp.Inventors: Jih-ru Hwu, Shwu-chen Tsay
-
Publication number: 20110165139Abstract: Provided are: an agent for promoting growth hormone-secretion, containing a milk-derived basic protein fraction as an active ingredient, with the promotion of growth hormone-secretion being mediated by the promotion of secretion of ghrelin having an effect for promoting growth hormone-secretion; and a method of promoting the secretion of ghrelin by using a milk-derived basic protein fraction. The agent for promoting growth hormone-secretion may be ingested on a daily basis and is highly safe even with its ingestion for a long period.Type: ApplicationFiled: March 10, 2011Publication date: July 7, 2011Applicant: SNOW BRAND MILK PRODUCTS CO., LTD.Inventors: Aiko ONO, Hiroaki MATSUYAMA, Yoshikazu MORITA, Atsushi SERIZAWA, Satoshi HIGURASHI
-
Publication number: 20110165138Abstract: The present invention relates generally to the field of obesity and complications arising therefrom and in particular to the control of obesity by inhibiting adipogenesis and related processes.Type: ApplicationFiled: June 17, 2009Publication date: July 7, 2011Applicant: HEALTHLINX LIMITEDInventors: Antonio Rajic, Dominic J. Autelitano, Ana K. Vrkic, Christopher G. Hosking, Leodevico L. Ilag
-
Patent number: 7972595Abstract: Methods and compositions for protecting and treating a muscarinic receptor in a subject in need thereof from dysfunction not resulting from oxidative stress, toxic actions of metals or metal ions, or infectious agents by administering a pyrophosphate analog.Type: GrantFiled: July 28, 2005Date of Patent: July 5, 2011Assignee: HealthPartners Research FoundationInventors: William H. Frey, II, John Randall Fawcett
-
Publication number: 20110150943Abstract: The invention relates to adhesives for medical applications and methods of their preparation and use.Type: ApplicationFiled: March 1, 2011Publication date: June 23, 2011Inventors: Andreas Werner Speitling, Philip Procter, Joachim Schomburg, Christian Schultz, Wolf-Dieter Jülich, Ulrike Lindequist, Frieder Schauer, Annett Mikolasch, Katrin Manda
-
Publication number: 20110150856Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.Type: ApplicationFiled: December 21, 2010Publication date: June 23, 2011Inventor: Sarah Bacus
-
Publication number: 20110135622Abstract: This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.Type: ApplicationFiled: February 16, 2011Publication date: June 9, 2011Applicant: Encore Health, LLCInventors: Jonathan S. Till, Ronald D. Blum
-
Publication number: 20110135712Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: ApplicationFiled: September 1, 2010Publication date: June 9, 2011Applicant: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles TAPOLSKY, David E. EMERSON, John MARSHALL, Tauseef AHMED, Allen COHN, Michael KURMAN, Manuel MODIANO
-
Publication number: 20110123566Abstract: Methods of modulating the immune response using pharmaceutical compositions containing crystalline adjuvants are described. In various embodiments the crystalline adjuvants are selected from the group consisting of monosodium urate (MSU), xanthine, basic calcium phosphate (BCP), calcium pyrophosphate dihydrate (CPPD), hydroxyapatite, calcium oxalate, cholesterol, lipid liquid, other crystalline lipids, lithium heparin, talc, and starch.Type: ApplicationFiled: September 10, 2010Publication date: May 26, 2011Applicant: The University of Massachusetts an agency of the Commonwealth of MassachusettsInventors: Kenneth L. ROCK, Yan SHI
-
Publication number: 20110117170Abstract: The present invention comprises compositions, methods, and devices for delivering angiogenic factors and signaling molecules to a target tissue, and controlling the release of these factors and signaling molecules to spatially and temporally restrict their release and dissemination, for the purposed promoting angiogenesis in target tissues.Type: ApplicationFiled: June 1, 2009Publication date: May 19, 2011Inventors: Lan Cao, David J. Mooney
-
Publication number: 20110117202Abstract: Methods and systems for producing a change in a medium. A first method and system (1) place in a vicinity of the medium at least one upconverter including a gas for plasma ignition, with the upconverter being configured, upon exposure to initiation energy, to generate light for emission into the medium, and (2) apply the initiation energy from an energy source including the first wavelength ?1 to the medium, wherein the emitted light directly or indirectly produces the change in the medium. A second method and system (1) place in a vicinity of the medium an agent receptive to microwave radiation or radiofrequency radiation, and (2) apply as an initiation energy the microwave radiation or radiofrequency radiation by which the agent directly or indirectly generates emitted light in the infrared, visible, or ultraviolet range to produce at least one of physical and biological changes in the medium.Type: ApplicationFiled: November 10, 2010Publication date: May 19, 2011Applicants: Immunolight, LLC, Duke UniversityInventors: Frederic A. Bourke, JR., Zakaryae Fathi, Ian Nicholas Stanton, Michael J. Therien, Paul Rath Stauffer, Paolo MacCarini, Katherine Sarah Hansen, Diane Renee Fels, Cory Robert Wyatt, Mark Wesley Dewhirst
-
Publication number: 20110117071Abstract: The present invention relates to an improved antimicrobial composition comprising a hydrogen peroxide source and one or more antimicrobial agents. Ideally, the invention relates to an antimicrobial composition comprising (i) hydrogen peroxide source and (ii) an antimicrobial agent and its associated use in therapy, particularly in the treatment of antimicrobial infections.Type: ApplicationFiled: March 26, 2009Publication date: May 19, 2011Applicant: INSTITUTE OF TECHNOLOGY SLIGOInventors: John Reginald Barrett, James Joseph Brennan, Thomas Patrick Patton